NCT04950920View on ClinicalTrials.gov

Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke

PHASE3CompletedINTERVENTIONAL
Enrollment

914

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

August 10, 2022

Study Completion Date

November 14, 2022

Conditions
Stroke
Interventions
DRUG

Y-2 sublingual tablets

30mg Edaravone+6mg d-borneo OR， Bid

DRUG

d-borneol

60 μg d-borneol OR， Bid

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijin

All Listed Sponsors
lead

Peking University Third Hospital

OTHER